Drug intelligence / Profile preview

adebrelimab + camrelizumab + apatinib

Development stage: Unknown
Lead developer: Hengrui Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

This is a triple combination therapy consisting of adebrelimab (anti-PD-L1 antibody), camrelizumab (anti-PD-1 antibody), and apatinib (VEGFR2 tyrosine kinase inhibitor). The combination is being investigated primarily for unresectable hepatocellular carcinoma (HCC). The CARES-310 study previously demonstrated that camrelizumab plus apatinib improved progression-free survival and overall survival in advanced HCC patients. This triple combination aims to further enhance clinical outcomes by adding the anti-PD-L1 antibody adebrelimab to the regimen.

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on adebrelimab + camrelizumab + apatinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adebrelimab + camrelizumab + apatinib.

Explore the full profile